Ara-290 RA10 KSD

Product Model/Code: RA10
Common Name: ARA-290; Chemical Name: Cibinetide
Specifications: 10 mg/vial, 10 vials/kit
Product Category: Research-grade synthetic 11-amino acid lyophilized peptide
Appearance: White, sterile lyophilized powder; requires reconstitution with bacteriostatic water or sterile water.

Clinically Proven Efficacy (Based on Formal Scientific Research)
Neuropathy Repair: Phase II clinical applications include treating diabetic peripheral neuropathic pain and small-fiber nerve damage associated with small-fiber neuropathy, thereby alleviating limb tingling, numbness, and hypersensitivity.
Systemic Tissue Protection and Anti-inflammatory Effects: Protection against renal ischemic injury, accelerated healing of skin wounds and pressure ulcers, and nerve repair following traumatic brain injury.
Vascular Endothelial Support: Improvement of capillary density in ischemic tissues and protection of cardiac and renal microvasculature.
Antioxidant and Anti-apoptotic Effects: Reduction of the likelihood of apoptosis following cellular injury and mitigation of tissue fibrosis.

Promotional context for fitness/glute training (supports recovery only; does not build muscle):
Alleviates delayed onset muscle soreness (DOMS) in the glutes and legs following high-intensity training and significantly reduces localized inflammation;
Repairs micro-tears in gluteal fascia, ligaments, and subcutaneous soft tissue caused by exercises like squats and hip thrusts;
Reduces bruising and swelling after glute workouts, shortens recovery time, and allows for increased training frequency;
Relieves nerve-related stinging pain and numbness in the glutes and lower limbs caused by exercise-induced strain;
Key distinction: It does not stimulate muscle satellite cell proliferation or increase glute muscle volume; it serves solely to aid in injury repair and recovery.

Short-term mild side effects
Local reactions: Transient redness, mild soreness/heaviness resolving spontaneously within 48 hours;
Mild systemic reactions: Mild headache, transient nausea, or fatigue in a small number of individuals;
Comparison with EPO: No risk of blood thickening, hypertension, thrombosis, or elevated hemoglobin levels.
VII. Potential long-term risks and contraindications